2022
Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study (P2-2.002)
Jensen C, Thiry A, Kim E, Lovergren M, Croop R, Coric V, L‘Italien G, Lipton R. Acute Treatment with Oral Rimegepant 75 mg Reduces Migraine-Related Disability in Adults With and Without a History of Triptan Treatment Failure: Results from a One-Year, Open-Label Safety Study (P2-2.002). Neurology 2022, 98 DOI: 10.1212/wnl.98.18_supplement.873.Peer-Reviewed Original Research
2020
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. The Lancet 2020, 397: 51-60. PMID: 33338437, DOI: 10.1016/s0140-6736(20)32544-7.Peer-Reviewed Original ResearchConceptsDouble-blind treatment phasePlacebo-controlled trialStudy medicationMigraine daysPreventive treatmentAdverse eventsPhase 2/3Observation periodTreatment phaseWeek 9Calcitonin gene-related peptide receptor antagonistMean numberInteractive web response systemPrimary efficacy endpointWeb response systemPeptide receptor antagonistEfficacy endpointPrimary endpointAcute treatmentEligible participantsReceptor antagonistPlaceboMigraineMedicationsRimegepantRimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine (1793)
McGinley J, L’Italien G, Thiry A, Croop R, Coric V, Lipton R. Rimegepant 75 mg Results in Reductions in Monthly Migraine Days: Secondary Analysis of a Multicenter, Open Label Long-term Safety Study of Rimegepant for the Acute Treatment of Migraine (1793). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1793.Peer-Reviewed Original ResearchAcute Treatment with Oral Rimegepant 75mg Reduces Migraine-Related Disability: Results from a One Year, Open-Label Safety Study (BHV3000-201) (1926)
L’Italien G, Croop R, Stock E, Thiry A, Lovegren M, Cowie K, Jensen C, Coric V, Lipton R. Acute Treatment with Oral Rimegepant 75mg Reduces Migraine-Related Disability: Results from a One Year, Open-Label Safety Study (BHV3000-201) (1926). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1926.Peer-Reviewed Original ResearchAcute Treatment of Migraine with Oral Rimegepant 75 mg Improves Health Related Quality of Life: Results from a Long-Term, Open-Label Safety Study (BHV3000-201) (1943)
Harris L, L’Italien G, Croop R, Stock E, Thiry A, Cowrie K, Lovegren M, Jensen C, Coric V, Lipton R. Acute Treatment of Migraine with Oral Rimegepant 75 mg Improves Health Related Quality of Life: Results from a Long-Term, Open-Label Safety Study (BHV3000-201) (1943). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.1943.Peer-Reviewed Original ResearchPatient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201) (2112)
Jensen C, Croop R, Lipton R, Stock E, Thiry A, Conway C, Lovegren M, Coric V, L’Italien G. Patient Preference and Improved Clinical Global Impression of Change with Rimegepant for the Acute Treatment of Migraine: Results from a Long-Term Open-Label Safety Study (Study 201) (2112). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2112.Peer-Reviewed Original ResearchRimegepant Has No Clinically Relevant Effect on ECG parameters at Therapeutic and Supratherapeutic Doses: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects (2117)
Hanna M, Coric V, Stringfellow J, Ivans A, Croop R. Rimegepant Has No Clinically Relevant Effect on ECG parameters at Therapeutic and Supratherapeutic Doses: A Thorough QT Study Versus Placebo and Moxifloxacin in Healthy Subjects (2117). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2117.Peer-Reviewed Original ResearchCardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays (2141)
Conway C, Croop R, Dubowchik G, Coric V, Lipton R. Cardiovascular Safety of Rimegepant 75 mg in 3 Randomized Clinical Trials and Systematic Evaluations from In Vitro, Ex Vivo, and In Vivo Nonclinical Assays (2141). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2141.Peer-Reviewed Original ResearchPhase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145)
Conway C, Dubowchik G, Croop R, Coric V. Phase 1 and 2 Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose Rimegepant as Compared to the Predicted Clinically Efficacious Dose Range (2145). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.2145.Peer-Reviewed Original ResearchOral Rimegepant Produces No Significant Effect on Blood Pressure When Administered Concomitantly with SC Sumatriptan (4007)
Hanna M, Ivans A, Stringfellow J, Jensen C, Coric V, Croop R. Oral Rimegepant Produces No Significant Effect on Blood Pressure When Administered Concomitantly with SC Sumatriptan (4007). Neurology 2020, 94 DOI: 10.1212/wnl.94.15_supplement.4007.Peer-Reviewed Original Research